European Registry of Transcatheter Repair for Tricuspid Regurgitation
EuroTR
1 other identifier
observational
3,000
1 country
1
Brief Summary
To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 23, 2023
CompletedFirst Submitted
Initial submission to the registry
February 27, 2024
CompletedFirst Posted
Study publicly available on registry
March 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
March 15, 2024
March 1, 2024
7.2 years
February 27, 2024
March 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause mortality
5 years
Secondary Outcomes (12)
Technical success
5 years
Procedural Safety
5 years
Heart Failure Biomarker
5 years
Dyspnea on exertion
5 years
Functional capacity
5 years
- +7 more secondary outcomes
Interventions
T-TEER using the PACAL or TriClip device
Eligibility Criteria
Patients treated with one of the following transcatheter devices for TV repair or replacement (e.g. PASCAL, TriClip, TricValve, Evoque, LuX-Valve)
You may qualify if:
- Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve
- Age ≥ 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LMU Klinikumlead
Study Sites (1)
LMU Klinikum
Munich, Bavaria, 81377, Germany
Related Publications (1)
Masiero G, Arturi F, Ceni S, Panza A, Kresoja KP, von Stein J, Fortmeier V, Koell B, Rottbauer W, Kassar M, Goebel B, Denti P, Achouh P, Rassaf T, Barreiro-Perez M, Boekstegers P, Ruck A, Zdanyte M, Adamo M, Vincent F, Schlegel P, Rosch S, Wild MG, Besler C, Toggweiler S, Brunner S, Grapsa J, Patterson T, Thiele H, Kister T, Sticchi A, De Carlo M, Voss F, Polzin A, Popolo Rubbio A, Bedogni F, Stolte T, Nestelberger T, Benito-Gonzalez T, Sanchez-Munoz E, Konstandin MH, Van Belle E, Metra M, Geisler T, Estevez-Loureiro R, Mahabadi AA, Karam N, Maisano F, Lauten P, Praz F, Kessler M, Kalbacher D, Rudolph V, Iliadis C, Lurz P, Hausleiter J, Stolz L, Tarantini G; EuroTR Investigators. Invasive Hemodynamics and Risk Stratification in T-TEER: Moving Beyond ESC Thresholds: EuroTR Registry Insights. Circ Cardiovasc Interv. 2025 Nov 14:e015964. doi: 10.1161/CIRCINTERVENTIONS.125.015964. Online ahead of print.
PMID: 41235431DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy chief
Study Record Dates
First Submitted
February 27, 2024
First Posted
March 12, 2024
Study Start
October 23, 2023
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
March 15, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share